Royalty Pharma plc (RPRX) has seen significant movements in their stocks, attracting investments from multiple institutional investors. Financial entities like Truist Financial Corp and Kingsview Wealth Management have invested in and Panagora Asset Management accumulating over 215,000 RPRX shares. Conversely, both Teacher Retirement System of Texas and Amalgamated Bank have reduced their holdings. Bias towards RPRX is mixed with some positive affirmation of the stock's performance while others caution potential unpleasant surprises and question of excess debt. Encouragingly, RPRX has shown a strong start to the year with solid operational metrics and beat Q1 earnings and revenue estimates. Notably, it announced a dividend of $0.21. There are predictions for an EPS growth by FY2023. This may reflect its robust growth and strategic acquisition efforts. Warren Buffet has shown interest in the pharmaco with a stake in Royalty Pharma. Lastly, RPRX is set to announce its first quarter 2024 financial results on May 9, 2024.
Royalty Pharma Stocks News Analytics from Tue, 16 Jun 2020 07:00:00 GMT to Sun, 19 May 2024 14:50:55 GMT -
Rating 6
- Innovation 4
- Information 8
- Rumor -2
